Reducing Risks and Delays in the Translation of Cell and Gene Therapy Innovations into Regulated Products

NAM Perspect. 2019 Sep 30:2019:10.31478/201909d. doi: 10.31478/201909d. eCollection 2019.
No abstract available

Publication types

  • Review

Grants and funding

The views expressed in this paper are those of the authors and not necessarily of the authors’ organizations, the National Academy of Medicine (NAM), or the National Academies of Sciences, Engineering, and Medicine (the National Academies). The paper is intended to help inform and stimulate discussion. It is not a report of the NAM or the National Academies.